Inhibition of Transglutaminase 2 Reduces Peritoneal Injury in a Chlorhexidine-Induced Peritoneal Fibrosis Model

• Published in: Laboratory investigation Vol. 103; no. 4; p. 100050
• Main Authors: Kunoki, Shunnosuke, Tatsukawa, Hideki, Sakai, Yukinao, Kinashi, Hiroshi, Kariya, Tetsuyoshi, Suzuki, Yasuhiro, Mizuno, Masashi, Yamaguchi, Makoto, Sasakura, Hiroyuki, Ikeno, Masashi, Takeuchi, Kosei, Ishimoto, Takuji, Hitomi, Kiyotaka, Ito, Yasuhiko
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.04.2023
• Subjects: Actins - metabolism; Animals; Chlorhexidine - adverse effects; Chlorhexidine - metabolism; chlorhexidine-induced model; EndMT; Endothelial Cells - metabolism; Fibrosis; Inflammation - metabolism; Mice; Mice, Knockout; peritoneal fibrosis; Peritoneal Fibrosis - chemically induced; Peritoneal Fibrosis - metabolism; Peritoneal Fibrosis - prevention & control; Peritoneum - pathology; Protein Glutamine gamma Glutamyltransferase 2; Rats; TGF-β1; Transforming Growth Factor beta - metabolism; Transforming Growth Factor beta1 - metabolism; transglutaminase; Vascular Endothelial Growth Factor A - metabolism; α-SMA; peritoneal fibrosis; α-SMA; transglutaminase; TGF-β1; EndMT; chlorhexidine-induced model
• DOI: 10.1016/j.labinv.2022.100050
• ISSN: 0023-6837

Long-term peritoneal dialysis (PD) is often associated with peritoneal dysfunction leading to withdrawal from PD. The characteristic pathologic features of peritoneal dysfunction are widely attributed to peritoneal fibrosis and angiogenesis. The detailed mechanisms remain unclear, and treatment targets in clinical settings have yet to be identified. We investigated transglutaminase 2 (TG2) as a possible novel therapeutic target for peritoneal injury. TG2 and fibrosis, inflammation, and angiogenesis were investigated in a chlorhexidine gluconate (CG)-induced model of peritoneal inflammation and fibrosis, representing a noninfectious model of PD-related peritonitis. Transforming growth factor (TGF)-β type I receptor (TGFβR-I) inhibitor and TG2-knockout mice were used for TGF-β and TG2 inhibition studies, respectively. Double immunostaining was performed to identify cells expressing TG2 and endothelial-mesenchymal transition (EndMT). In the rat CG model of peritoneal fibrosis, in situ TG2 activity and protein expression increased during the development of peritoneal fibrosis, as well as increases in peritoneal thickness and numbers of blood vessels and macrophages. TGFβR-I inhibitor suppressed TG2 activity and protein expression, as well as peritoneal fibrosis and angiogenesis. TGF-β1 expression, peritoneal fibrosis, and angiogenesis were suppressed in TG2-knockout mice. TG2 activity was detected by α-smooth muscle actin-positive myofibroblasts, CD31-positive endothelial cells, and ED-1-positive macrophages. CD31-positive endothelial cells in the CG model were α-smooth muscle actin-positive, vimentin-positive, and vascular endothelial-cadherin-negative, suggesting EndMT. In the CG model, EndMT was suppressed in TG2-knockout mice. TG2 was involved in the interactive regulation of TGF-β. As inhibition of TG2 reduced peritoneal fibrosis, angiogenesis, and inflammation associated with TGF-β and vascular endothelial growth factor-A suppression, TG2 may provide a new therapeutic target for ameliorating peritoneal injuries in PD.